Pharma News

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Daiichi Sankyo for its antibody-drug conjugate (ADC) datopotamab deruxtecan, which is designed...

Goal: Advance lead therapy into Phase 1 testing in patients by mid-2025.

Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity. The study published in Nature shows the drastic economic cost of obesity through...

NurExone Biologic Inc., a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portf...

Five Chinese-linked biotechnology firms won a reprieve Saturday when negotiators on a key defense bill decided not to include legislation blacklisting the companies from new federally funded research ...

By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.

After offloading a big chunk of their Japanese generics joint venture in 2020, Teva and Takeda have decided to divest the business in its entirety so they can each focus on their innovative medicines.

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

Ipsen has announced that it will be gaining exclusive global rights to Biomunex Pharmaceuticals’ pre-clinical T cell engager (TCE) in a deal worth up to $610m, marking an expansion to the co...

NLS Pharmaceutics Ltd., a Swiss biopharmaceutical company with a market capitalization of $5.75 million, has announced encouraging results from its ongoing preclinical study of a novel dual orexin rec...

Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease sector.

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the...